Physician profile
Gabriel Tanson
NPI 1023053105
$12,997.12
in general payments reported to CMS, 2019-2025
55 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,244 · 2020: $2,267 · 2021: $2,190 · 2022: $1,817 · 2023: $1,596 · 2024: $1,449 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,479.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,651.53 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $1,400.24 | 2020-2025 | Vraylar, Qulipta, Linzess |
| Novo Nordisk INC | $1,229.53 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $781.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $633.98 | 2019-2024 | Airsupra, Farxiga |
| Allergan, INC. | $602.75 | 2019-2020 | |
| Amgen INC. | $545.31 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Pfizer INC. | $523.77 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $446.68 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $409.89 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $393.15 | 2019-2022 | |
| Lilly USA, LLC | $366.61 | 2019-2024 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $333.56 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $305.39 | 2019-2023 | Austedo, Austedo Xr |
| Sanofi-Aventis U.S. LLC | $284.24 | 2019-2023 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Tanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.